Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

RSV-NET data showed that RSV hospitalization rates among infants aged 0 to 7 months were an estimated 43% (95% confidence ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein vaccine (Abrysvo) or nirsevimab (Beyfortus), Stephanie Irving, MHS, of the ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

On the heels of a fall and winter that saw hundreds of Alberta babies and toddlers hospitalized and two young children die ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence.

HealthDay News — In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized against respiratory syncytial virus (RSV).

A total of 69 infants (median age at admission, 2.7 months; 56.5% boys) who received nirsevimab and were hospitalised for RSV-related LRTI were included. Cases were classified as breakthrough (n ...

Nirsevimab is a seasonal immunization that targets RSV in infants. As a monoclonal antibody—a protein that can bind to a specific target—nirsevimab binds to a particular area of the virus and ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...